02171.HK
CARsgen Therapeutics Holdings Limited
HKSE · Healthcare · Biotechnology · CN
HKD 13.43
+2.36%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 220.7M | 125.7M | 39.4M | — | — |
| Cost of Revenue | 85.6M | 45.7M | 24.7M | — | — |
| Gross Profit | 135.1M | 79.9M | 14.7M | — | — |
| Operating Expenses | |||||
| R&D Expense | 598.4M | 245.4M | 466.2M | 661.7M | 680.3M |
| SG&A Expense | 191.6M | 71.8M | 162.8M | 133.3M | 136.6M |
| General & Admin Expense | 170.6M | 67.5M | 155.2M | 127.8M | 135.1M |
| Selling & Marketing Expense | 13.8M | 1.4M | 875.0K | 5.5M | 1.5M |
| Other Expenses | (32.8M) | (133.0M) | 193.9M | (27.3M) | 64.4M |
| Total Operating Expenses | 757.3M | 184.2M | 822.9M | 767.6M | 881.3M |
| Cost and Expenses | 842.9M | 229.9M | 847.6M | 767.6M | 881.3M |
| Operating Income (EBIT) | (622.2M) | (104.2M) | (808.2M) | (767.6M) | (881.3M) |
| Non-Operating | |||||
| Interest Income | 43.4M | 14.8M | 41.9M | 72.8M | 27.6M |
| Interest Expense | 13.9M | 6.9M | 5.7M | 4.7M | 15.5M |
| Net Interest Income | 29.5M | 7.9M | 36.2M | 68.1M | 12.0M |
| Other Non-Op Income/Expense | 2.2M | 1.3M | 10.4M | 20.3M | (9.7M) |
| Non-Operating Income (excl Interest) | (26.8M) | 123.7M | (246.0M) | 17.4M | (75.7M) |
| EBT (Pre-Tax Income) | (620.0M) | (102.9M) | (797.8M) | (747.4M) | (891.0M) |
| Income Tax Expense | 346.0K | — | 346.0K | 407.0K | 1.3M |
| Bottom Line | |||||
| Net Income | (611.1M) | (97.9M) | (798.1M) | (747.8M) | (892.2M) |
| Earnings from Cont. Ops | (620.3M) | (102.9M) | (798.1M) | (747.8M) | (892.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (611.1M) | (97.9M) | (798.1M) | (747.8M) | (892.2M) |
| Per Share | |||||
| Basic EPS | (HK$1.15) | (HK$0.18) | (HK$1.44) | (HK$1.34) | (HK$1.62) |
| Diluted EPS | (HK$1.15) | (HK$0.18) | (HK$1.44) | (HK$1.34) | (HK$1.62) |
| Revenue Per Share | HK$0.40 | HK$0.23 | HK$0.07 | HK$0.00 | HK$0.00 |
| Shares | |||||
| Basic Shares Outstanding | 551.5M | 552.1M | 552.9M | 556.1M | 551.6M |
| Diluted Shares Outstanding | 551.5M | 552.1M | 552.9M | 556.1M | 551.6M |
| Profitability Metrics | |||||
| EBITDA | (530.0M) | (203.9M) | (497.1M) | (717.6M) | (748.7M) |
| D&A | 65.4M | 24.0M | 65.1M | 67.4M | 56.9M |
| EBIT | (595.4M) | (227.9M) | (562.2M) | (785.0M) | (805.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026